This Phase II study, known as the STRONG Study, evaluated three dose levels of NB S101 (strontium malonate) and one dose level of Protelos, which is approved for treatment and prevention of osteoporosis in Europe. The reductions in serum CTX-1 compared to the control group were 13.5% in the group receiving the lowest dose of NB S101, 0.75grams, 15.5% in the group receiving 1gram of NB S101, and 22.2% in the group receiving 2grams of NB S101 (p<0.001 for all doses vs. control). The trial also investigated the effects of NB S101 on bone mineral density (BMD) at specific sites including lumbar spine, total hip and femoral neck as secondary endpoints of the trial. At three months, NB S101 significantly increased lumbar spine BMD at all doses of NB S101 tested, with the most significant increase of 2.66% (p<0.01) for the 2grams dose, the highest dose of NB S101 tested. Protelos, also a 2grams dose, significantly increased lumber spine BMD by 1.96% (p<0.05). Philip Young, Osteologix's president and CEO, said: "The STRONG study validates the approach we have taken and our belief that NB S101 has a unique and powerful effect on bone. We believe that the success of strontium ranelate in Europe decreases the risk of our development of NB S101. We look forward to sharing this outstanding Phase II data with regulatory authorities in the US and Europe in the coming months and moving forward into late-stage clinical trials as we seek to bring this drug to the millions of patients around the world who suffer from osteoporosis."